Leishmania Inhibitors Derived from Deep-Sea Coral

Competitive Advantages

  • Specific inhibition of Leishmania donovani parasites
  • A natural drug candidate
  • Does not produce toxic side effects

Summary

Our researchers have identified a novel metabolite derived from an Antarctic marine coral that shows promise as a new treatment option for leishmaniasis infections. Antactic marine invertebrates are being investigated for their natual chemical protective mechanisms used against predators. This natural product chemistry is ideal for new drug development efforts. The identified metabolite has exhibited specific inhibition of Leishmania donovani parasites in laboratory settings.

A Leishmaniasis Infection at the Cellular Level

Desired Partnerships

  • License
  • Sponsored Research
  • Co-Development
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Leishmania Inhibitors Utility United States 16/417,117 10,898,460 5/20/2019 1/26/2021 5/20/2039